Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Loxoprofen sodium is a non-steroidal anti-inflammatory drug (NSAID) belonging to the propionic acid derivative group, which also includes ibuprofen and naproxen. It functions as a non-selective inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the biosynthesis of prostaglandins that mediate pain, fever, and inflammation. Loxoprofen is administered as a prodrug and is converted into its active trans-alcohol metabolite following absorption. The transdermal patch formulation, marketed under brand names such as Loxonide and Loxonin, is widely used for the topical relief of pain and inflammation associated with chronic conditions like osteoarthritis, as well as acute musculoskeletal pain and traumatic injuries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on loxoprofen sodium.